Bladder cancer: diagnosis and treatment
KC DeGEORGE, HR Holt, SC Hodges - American family physician, 2017 - aafp.org
Bladder cancer is the sixth most prevalent malignancy in the United States and causes more
than 16,000 deaths annually. The most common clinical presentation is asymptomatic …
than 16,000 deaths annually. The most common clinical presentation is asymptomatic …
The economics of bladder cancer: costs and considerations of caring for this disease
RS Svatek, BK Hollenbeck, S Holmäng, R Lee, SP Kim… - European urology, 2014 - Elsevier
Context Due to high recurrence rates, intensive surveillance strategies, and expensive
treatment costs, the management of bladder cancer contributes significantly to medical …
treatment costs, the management of bladder cancer contributes significantly to medical …
Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation …
RH Mak, D Hunt, WU Shipley, JA Efstathiou… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Multiple prospective Radiation Therapy Oncology Group (RTOG) protocols have
evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive …
evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive …
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Chemotherapy-resistant urothelial carcinoma has no uniformly curative therapy.
Understanding how selective pressure from chemotherapy directs the evolution of urothelial …
Understanding how selective pressure from chemotherapy directs the evolution of urothelial …
Bladder cancer
Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle …
VT Packiam, DL Lamm, DA Barocas, A Trainer… - … Oncology: Seminars and …, 2018 - Elsevier
Objectives CG0070 is a replication-competent oncolytic adenovirus that targets bladder
tumor cells through their defective retinoblastoma pathway. Prior reports of intravesical …
tumor cells through their defective retinoblastoma pathway. Prior reports of intravesical …
Reporting radical cystectomy outcomes following implementation of enhanced recovery after surgery protocols: a systematic review and individual patient data meta …
Abstract Context Enhanced Recovery After Surgery (ERAS) is a perioperative approach to
managing surgical patients. The impact of ERAS on radical cystectomy (RC) outcomes …
managing surgical patients. The impact of ERAS on radical cystectomy (RC) outcomes …
Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses
AH Al-Zalabani, KFJ Stewart, A Wesselius… - European journal of …, 2016 - Springer
Abstract Each year, 430,000 people are diagnosed with bladder cancer. Due to the high
recurrence rate of the disease, primary prevention is paramount. Therefore, we reviewed all …
recurrence rate of the disease, primary prevention is paramount. Therefore, we reviewed all …
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
Trithorax-like group complex containing KDM6A acts antagonistically to Polycomb-
repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the …
repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the …
Raman spectroscopy for cancer detection and cancer surgery guidance: translation to the clinics
Oncological applications of Raman spectroscopy have been contemplated, pursued, and
developed at academic level for at least 25 years. Published studies aim to detect pre …
developed at academic level for at least 25 years. Published studies aim to detect pre …